About Alpha-1 DeficiencyThe Zemaira® DifferenceAlpha-1 Detection ResourcesZemaira® Patient Programs and ServicesOrdering Zemaira®Medical ResourcesImportant Safety InformationPrescribing InformationZemaira® for consumers

Contact Us

Consumer Services or Programs

If your question is about a medical condition, then you should consult with a healthcare professional or, in the case of an emergency, call 911 immediately.

Standard business hours for CSL Behring are 8:30 am to 5:00 pm Eastern time.

CSL Behring Headquarters
Phone: 610-878-4000
Fax: 610-878-4009
Location: North America Headquarters
Address: P.O. Box 61501
1020 First Avenue
King of Prussia, PA 19406 USA
Consumer Affairs
For Consumer Information
Phone: 888-508-6978
Fax: 610-878-4008
Medical Affairs
Phone: 800-504-5434
Fax: 610-878-4007
Adverse Events
Phone: 610-878-4193
Phone (After Business Hours): 866-915-6958

All fields marked with an asterisk (*) are required.

  •  

    •    

Prior to submitting your information, please review our Privacy Policy.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira® are not available.

Zemaira® may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira® is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.